{"id":550659,"date":"2021-06-30T23:02:01","date_gmt":"2021-06-30T23:02:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=550659"},"modified":"2021-06-30T23:02:01","modified_gmt":"2021-06-30T23:02:01","slug":"vernal-keratoconjunctivitis-market-share-trends-epidemiology-forecast-till-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-market-share-trends-epidemiology-forecast-till-2030_550659.html","title":{"rendered":"Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030\" src=\"https:\/\/www.abnewswire.com\/uploads\/1585648587.jpeg\" alt=\"Vernal Keratoconjunctivitis Market, Share, Trends, Epidemiology Forecast Till 2030\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP      <\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cVernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.\n<\/div>\n<p style=\"text-align: justify;\">Vernal Keratoconjunctivitis (VKC) is a bilateral, usually seasonally recurrent, allergic inflammation of the conjunctiva, characterized by limbal gelatinous hypertrophy and\/or upper tarsal giant conjunctival papillae.<\/p>\n<p style=\"text-align: justify;\">The&nbsp;<a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-market\"  target=\"_blank\">Vernal keratoconjunctivitis market&nbsp;<\/a>report provides current treatment practices, emerging drugs, Vernal keratoconjunctivitis market share of the individual therapies, current and forecasted Vernal keratoconjunctivitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Vernal keratoconjunctivitis treatment practice\/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal Keratoconjunctivitis Market Insight<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The <a rel=\"nofollow\" class=\"seoquake-nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/vernal-keratoconjunctivitis-market\"  target=\"_blank\">market size of Vernal Keratoconjunctivitis (VKC)<\/a> in total markets in 2017 was USD 307.89 million<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Vernal Keratoconjunctivitis Market Drivers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Rise in the Prevalence<\/li>\n<li>Disease awareness and diagnosis<\/li>\n<li>Research and development<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal Keratoconjunctivitis Market Barriers<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Weak emerging drug pipeline<\/li>\n<li>Diagnostic Barriers<\/li>\n<li>Limited approved therapies<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Vernal keratoconjunctivitis Market Outlook<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>Treatment of VKC requires multiple approaches that include conservative measures and pharmacologic treatment. Patients and parents should be made aware of the prolonged duration of disease, its chronic evolution, and possible complications. Treatment should be based on the duration and frequency of symptoms and the severity of corneal involvement.<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">Currently available topical drugs for allergic conjunctivitis belong to several pharmacologic classes, such as&nbsp;<span>vasoconstrictors<\/span>,&nbsp;<span>antihistamines<\/span>,&nbsp;<span>mast cell stabilizers<\/span>, &lsquo;<span>dual-acting<\/span>&rsquo;&nbsp;<span>agents<\/span>&nbsp;(with&nbsp;<span>antihistaminic<\/span>&nbsp;and&nbsp;<span>mast cell stabilizing properties<\/span>),&nbsp;<span>non-steroidal anti-inflammatory agents<\/span>,&nbsp;<span>corticosteroids<\/span>, and&nbsp;<span>immunosuppressive drugs<\/span>.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>Mast cell stabilizers<\/span>&nbsp;are the&nbsp;<em>first-line drugs<\/em>&nbsp;for VKC. Several studies have demonstrated the efficacy of 2% and 4% sodium cromoglicate (DSCG, cromolyn),&nbsp;<span>nedocromil sodium<\/span>&nbsp;2%,&nbsp;<span>lodoxamide tromethamine<\/span>&nbsp;0.1%, and&nbsp;<span>spaglumic acid<\/span>&nbsp;4%.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">Ocular drugs with antihistaminic activity may offer therapeutic advantages to patients with allergic conjunctivitis, including VKC, by inhibiting proinflammatory cytokine secretion from conjunctival epithelial cells. The first-generation antihistamines&nbsp;<span>pheniramine<\/span>&nbsp;and&nbsp;<span>antazoline<\/span>&nbsp;have a long safety record. The newer antihistamines such as&nbsp;<span>levocabastine hydrochloride 0.5%<\/span>&nbsp;and&nbsp;<span>emedastine difumarate 0.05%&nbsp;<\/span>have a longer duration of action (4&ndash;6 h) and are better tolerated than their predecessors.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">A meta-analysis of randomized clinical trials in VKC showed a large number of studies evaluated the efficacy of common anti-allergic eye drops (<em>levocabastine<\/em>,&nbsp;<em>lodoxamide<\/em>,&nbsp;<em>mipragoside<\/em>,&nbsp;<em>N-acetyl aspartyl glutamic acid<\/em>,&nbsp;<em>nedocromil sodium<\/em>,&nbsp;<em>DCG<\/em>). Among these,&nbsp;<span>lodoxamide<\/span>&nbsp;appeared to be the most effective.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>Papilock mini<\/span>&nbsp;and&nbsp;<span>Verkazia<\/span>&nbsp;both produced by Santen (Osaka, Japan) are specifically indicated for the treatment of VKC.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">Generally, NSAIDs employed in ocular allergy treatment inhibit both cyclooxygenase (COX)-1 and COX-2 enzymes. Also,&nbsp;<em>Ketorolac<\/em>,&nbsp;<em>diclofenac<\/em>&nbsp;and&nbsp;<em>pranoprofen<\/em>&nbsp;may be valid alternatives to steroids, since they have a proven effect on itching, intercellular adhesion molecule-1 expression, and tear tryptase levels. Indomethacin 1%, ketorolac 0.5%, and diclofenac 0.1% have shown effectiveness in the treatment of VKC.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>Aspirin<\/span>&nbsp;0.5&ndash;1 g\/day has been shown as a steroid-sparing factor in the treatment of VKC; however, it should be used with caution because of the well-known possible side effects.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">In severe cases, systemic treatment with T-lymphocyte signals transduction inhibitors such as Cyclosporine A or tacrolimus may ameliorate both the dermatologic and ocular manifestations in critical patients who are refractory to conventional treatment.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\"><span>Omalizumab<\/span>, an anti-IgE recombinant, humanized, non-anaphylactogenic antibody, directed against the receptor-binding domain of IgE, may be used in VKC patients with high levels of total serum IgE.&nbsp;<span>Calcineurin inhibitors&nbsp;<\/span>are off-label treatments in the European Union.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">As discussed, the current treatment for VKC depends solely on the use of antihistamines, mast cell inhibitors, and several other classes. But till now the treatment is only supportive and is not that effective. But due to the advancement of technology and a better understanding of the disease, several companies are trying to modify the treatment of VKC.<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for sample pages<\/strong>&nbsp;@&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/vernal-keratoconjunctivitis-market\" target=\"_blank\"><strong>Vernal keratoconjunctivitis (VKC) Market Report&nbsp;<\/strong><\/a><\/p>\n<p style=\"text-align: justify;\"><strong>Table of contents<\/strong><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>1. Key Insights<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>2. Executive Summary of Vernal keratoconjunctivitis (VKC)<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>3. Vernal keratoconjunctivitis (VKC): Market Overview at a Glance<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.1. Total Market Share (%) Distribution of VKC in 2017<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>3.2. Total Market Share (%) Distribution of VKC in 2030<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>4. Disease Background and Overview: Vernal keratoconjunctivitis (VKC<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>5. Case Report<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>6. Epidemiology and Patient Population<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>7. United States Epidemiology<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>8. EU5 Epidemiology<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>8.2. Germany Epidemiology<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.3. France Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.4. Italy Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.5. Spain Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">8.6. United Kingdom Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">9. Japan Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">10. MEA Region Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.1. Assumptions and Rationale<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>10.2.Saudi Arabia Epidemiology<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">10.3.Egypt Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">11. China Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">12. Russia Epidemiology<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">13. Current Treatment and Medical Practices<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.1. Treatment of VKC<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.2. Practical management of VKC<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>13.3. Treatment Guidelines<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">14. Unmet Needs<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>15. Marketed Drugs<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.1. Verkazia\/Verkacia: Santen<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">15.2. Lodoxamide\/Alomide: Novartis Pharmaceuticals\/Alcon<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">15.3. Talymus\/Tacrolimus: Senju Pharmaceutical<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16. Emerging Drugs<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>16.1. Antolimab (AK002): Allakos<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.2. Bertilimumab\/iCo-008: iCo Therapeutics<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">16.3. Nomacopan: Akari Therapeutics<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">17. Vernal Keratoconjunctivitis (VKC): 7MM Market Analysis<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">18. United States<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">19. EU-5 countries<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>19.1.Germany Market Size<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.2.France Market Size<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.3.Italy Market Size<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.4.Spain Market Size<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">19.5.United Kingdom Market Size<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">20. Japan<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>20.1. Japan Market Size<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21. MEA countries Market Outlook<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>21.1.Saudi Arabia Market Size<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">21.2.Egypt Market Size<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">22. China: Market Outlook<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>22.1. China Market Size<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">23. Russia Market Outlook<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\"><span>23.1. Russia Market Size<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-2\" style=\"text-align: justify;\">24. Market Drivers<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>25. Market Barriers<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>26. Reimbursement and Market Access<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>27. SWOT Analysis<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>28. KOL Views<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>29. Appendix<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p class=\"ql-indent-1\" style=\"text-align: justify;\">30. DelveInsight Capabilities<\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>31. Disclaimer<\/span><\/p>\n<p class=\"ql-align-justify\" style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span>32. About DelveInsight<\/span><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56407.html\" rel=\"nofollow\">DelveInsight<\/a><br \/><strong>Contact Person:<\/strong> Shruti Thakur<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=vernal-keratoconjunctivitis-market-share-trends-epidemiology-forecast-till-2030\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +919650213330<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=vernal-keratoconjunctivitis-market-share-trends-epidemiology-forecast-till-2030\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight\u2019s \u201cVernal keratoconjunctivitis Market Insights, Epidemiology, and Market Forecast-2030\u201d report delivers an in-depth understanding of the Vernal keratoconjunctivitis, historical and forecasted epidemiology as well as the Vernal keratoconjunctivitis market trends in the United States, EU5 (Germany, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/vernal-keratoconjunctivitis-market-share-trends-epidemiology-forecast-till-2030_550659.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[406,423,420,403,404],"tags":[],"class_list":["post-550659","post","type-post","status-publish","format-standard","hentry","category-Pharmaceuticals-Biotech","category-Professional-Services","category-Science","category-UK","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=550659"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/550659\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=550659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=550659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=550659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}